argenx SE
VYVGART
ocular myasthenia gravis
Resolved
98days ago
Catalyst readout · ~ Mar 31, 2026 estimated
What's at stake
A key catalyst for VYVGART (ocular myasthenia gravis) is expected ~ Mar 31, 2026.
Primary source
· SEC 6-K
verified 12h ago
“its expectation that it will submit a Supplemental Biologics License Application (sBLA) for VYVGART for oMG to the U.S. FDA by end of third quarter 2026”